Last updated: February 12, 2026
What is the case about?
LEO Pharma A/S filed a patent infringement lawsuit against Teva Pharmaceuticals USA, Inc., alleging Teva’s marketing and sale of a generic version of LEO’s topical psoriasis treatment, Enstilar (calcipotriol and betamethasone dipropionate). The case focuses on patent rights related to the composition and method claims protecting Enstilar.
When and where did it occur?
The case filed in the United States District Court for the District of New Jersey on January 17, 2019, under docket number 1:19-cv-01282. It involves patent infringement claims under the Hatch-Waxman Act, section 271.
What patents are involved?
LEO Pharma asserted one patent, U.S. Patent No. 9,649,369, titled "Topical Pharmaceutical Composition", granted on May 16, 2017. The patent claims cover the specific combination of calcipotriol and betamethasone dipropionate in a topical composition for treating psoriasis.
Key patent features:
- Patent term expiring October 10, 2030.
- Claims focus on the specific ratios, formulation, and method of delivery for psoriasis treatment.
What are the core legal issues?
- Validity of the patent: Teva challenged the patent’s validity, asserting anticipated prior art and obviousness.
- Infringement: Teva's generic product, Calcipotriol and Betamethasone Dipropionate Topical Foam, allegedly infringes on the patent claims.
What procedural developments occurred?
- Initially, Teva filed an Abbreviated New Drug Application (ANDA) seeking FDA approval for a generic version of Enstilar.
- LEO Pharma responded with a patent infringement suit, triggering automatic 30-month stay under the Hatch-Waxman process.
- The defendant filed counterarguments, including allegations of patent invalidity based on prior art references.
- Discovery included technical disclosures, prior art references, and formulations.
- In 2021, the court scheduled settlement negotiations and motions for summary judgment.
What is the current status?
- As of the latest update, the case is in pre-trial phase, pending dispositive motions.
- The parties indicated ongoing settlement discussions but no formal resolution as of mid-2023.
- Patent infringement claims remain in effect, with no publicly disclosed court ruling.
Litigation Risks and Strategic Considerations
- Patent strength: The patent’s narrow claims around specific formulations could be challenged as obvious or anticipated.
- Market impact: If Teva succeeds in invalidating the patent, it risks significant market share for Enstilar.
- Regulatory routes: Patents within pharmaceutical filings influence exclusivity periods; invalidation shortens market protection.
- Settlement potential: Litigation delay may lead to licensing or settlement, as seen in similar cases (e.g., Amgen v. Sandoz).
Financial and Commercial Implications
- Enstilar's sales reached approximately $340 million globally in 2022, with a significant portion in the US.
- Patent litigation delays could impact Teva’s market entry plans, influencing pricing, competition, and revenue projections.
- Winning or losing affects brand exclusivity, influencing R&D investments for similar patent-protected formulations.
Comparative Industry Context
- Related cases feature challenges to topical dermatological formulations’ patents, e.g., Sandoz vs. Amgen on biosimilars.
- Patent litigation often extends over multiple years, with some cases concluding after 4-5 years of proceedings.
Key Takeaways
- The case highlights typical patent challenges in the pharmaceutical industry, balancing innovation protection with generic entry.
- As of mid-2023, no final court ruling or settlement emerges, leaving market and legal risks unresolved.
- Patent validity defenses remain a critical component for generics pursuing market entry.
- Company strategies often include settlement or licensing to mitigate litigation costs and expedite market access.
- The outcome influences patent strategies, exclusivity periods, and competitive positioning within dermatology pharmaceuticals.
FAQs
-
What is the basis for Teva's challenge to the patent?
Teva asserts prior art and obviousness of the claimed composition, aiming to invalidate or narrow patent scope.
-
How long could this litigation last?
Patent infringement cases typically span 3-5 years, depending on procedural complexities and settlement delays.
-
What would happen if Teva’s challenges succeed?
The patent could be invalidated, allowing Teva to market generic versions of Enstilar, potentially reducing market share and revenue for LEO Pharma.
-
Are there other patents involved besides the '369 patent?
As of current records, only the '369 patent is asserted, though additional patents could be involved in later stages.
-
What are typical defenses LEO Pharma employs?
LEO likely defends patent validity by emphasizing novelty, inventive step, and non-obviousness, supported by patented formulation data.
Sources
[1] U.S. Patent No. 9,649,369, issued May 16, 2017.
[2] Court docket 1:19-cv-01282, District of New Jersey.
[3] FDA ANDA filings and industry reports on Enstilar sales.
